Steris (STE)
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$247.91+7.16%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-11-04
Research Workspace
Put STE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS of $11.1 to $11.3 in fiscal 2027: Diluted EPS: $2.04 per share.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 19% growth a year, above the roughly 9% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskSTE's growth engine must keep compounding to justify the current valuation. Revenue grew 7% year over year in the latest quarter. The company beat earnings estimates by 2% in Q1 FY2027. STE trades at 22x earnings versus a 29x peer median. The price reflects less growth than our forecast. The primary pillar is under pressure from fiscal 2027 EPS targets. Our model puts the next-quarter miss probability near 22%. Peer multiples imply a price about 15% below where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. STE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering STE (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare STE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| STE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put STE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase revenue by 7-8% in fiscal 2027
M&A and guidance support revenue growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase revenue by 7-8% in fiscal 2027
Earnings beat supports revenue growth objective.
Acquisition aligns with growth strategy and expands product offerings.
Acquisition aligns with growth and capital allocation objectives.
Q4 miss raises concerns about future revenue growth.
EPS miss indicates potential revenue growth issues.